Immediate Corticosteroid Therapy and Rituximab to Prevent Generalization in Ocular Myasthenia: a PROBE Multicenter Open-label Randomized Controlled Trial.

PHASE3RecruitingINTERVENTIONAL

Enrollment

128

Participants

Timeline

Start Date

April 29, 2025

Primary Completion Date

June 30, 2028

Study Completion Date

June 30, 2029

Conditions

Ocular Myasthenia Gravis

Interventions

DRUG

immediate treatment with corticosteroids

Immediate standardized treatment with corticosteroids. Standardized treatment in the experimental arm will start at 0.5mg/kg/d prednisone.

DRUG

addition of rituximab if recurrence

rituximab added if ocular symptoms reappear as corticosteroids are tapered off. Rituximab will be given at a dose of 500mg/6months for 12 months.

Trial Locations (1)

RECRUITING

Fondation Adolphe de Rothschild, Paris

All Listed Sponsors

lead

Fondation Ophtalmologique Adolphe de Rothschild

NETWORK